Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn's disease.

Abstract:

Background:Recent evidence has shown that the complete blood count (CBC) is abnormal in patients with Crohn's disease (CD). We aimed to investigate an effective CBC parameter and explore its impact on disease activity in a large CD cohort. Methods:We performed a retrospective analysis of patients with established CD who underwent clinically indicated endoscopy at four tertiary centres in China between 2016 and 2020. Individual variables of the Simple Endoscopic Score for CD, CBC parameters, C-reactive protein (CRP) levels, erythrocyte sedimentation rate, and faecal calprotectin (FC) were independently reviewed by different investigators. The hold-out method was used to verify the predictive power of the established model. Results:Data from a total of 1388 endoscopic procedures performed for 882 eligible CD patients were available with routine blood parameters and related indicators. The model using platelet-to-lymphocyte percentage ratio (PLpR) had high accuracy for identifying patients in endoscopic remission (ER), with an area under the curve (AUC) of 0.785 [95% confidence interval (CI): 0.784-0.787], which was comparable with that for CRP (AUC: 0.775, 95% CI: 0.774-0.777). Notably, the AUC of PLpR was significantly higher than that of CRP in patients with colonic disease and with a history of surgery. Moreover, after combining the FC with PLpR, the AUC value of FC + PLpR increased up to 0.892 (95% CI: 0.890-0.894) for identifying ER. Conclusions:We explored an index (PLpR) to identify CD patients in ER based on platelet and lymphocyte percentage from the CBC. PLpR helped evaluate the degree of disease activity and monitor the therapeutic response.

authors

Chen R,Li L,Chao K,Hong M,Cao Q,Ye L,Zhou G,Fang X,Guo H,Cao X,Ye X,Zeng Z,Chen M,Zhang S

doi

10.1177/1756284820979442

subject

Has Abstract

pub_date

2020-12-21 00:00:00

pages

1756284820979442

eissn

1756-283X

issn

1756-2848

pii

10.1177_1756284820979442

journal_volume

13

pub_type

杂志文章
  • Clostridium difficile infection: management strategies for a difficult disease.

    abstract::Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X13508519

    authors: Khanna S,Pardi DS

    更新日期:2014-03-01 00:00:00

  • Targeting mucosal healing in Crohn's disease: what the clinician needs to know.

    abstract::In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284819856865

    authors: Klenske E,Bojarski C,Waldner M,Rath T,Neurath MF,Atreya R

    更新日期:2019-06-14 00:00:00

  • Prophylaxis of hepatitis B infection in solid organ transplant recipients.

    abstract::Rates of transmission of hepatitis B virus (HBV) infection from organ donors with HBV markers to recipients along with reactivation of HBV during immunosuppression following transplantation have fallen significantly with the advent of hepatitis B immune globulin (HBIg) and effective antiviral therapy. Although the ava...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X13487942

    authors: John S,Andersson KL,Kotton CN,Hertl M,Markmann JF,Cosimi AB,Chung RT

    更新日期:2013-07-01 00:00:00

  • Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients.

    abstract:Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819858511

    authors: Mori H,Suzuki H,Omata F,Masaoka T,Asaoka D,Kawakami K,Mizuno S,Kurihara N,Nagahara A,Sakaki N,Ito M,Kawamura Y,Suzuki M,Shimada Y,Sasaki H,Matsuhisa T,Torii A,Nishizawa T,Mine T,Ohkusa T,Kawai T,Tokunaga K,Tak

    更新日期:2019-07-04 00:00:00

  • Review of the epidemiology and burden of ulcerative colitis in Latin America.

    abstract::The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incide...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820931739

    authors: Kotze PG,Steinwurz F,Francisconi C,Zaltman C,Pinheiro M,Salese L,Ponce de Leon D

    更新日期:2020-07-09 00:00:00

  • Fully covered self-expandable metal stent in the treatment of postsurgical colorectal diseases: outcome in 29 patients.

    abstract:BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X15610052

    authors: Cereatti F,Fiocca F,Dumont JL,Ceci V,Vergeau BM,Tuszynski T,Meduri B,Donatelli G

    更新日期:2016-03-01 00:00:00

  • Bilio-pancreatic endoscopy during COVID-19 pandemic.

    abstract::On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820935187

    authors: Bove V,Schepis T,Boškoski I,Landi R,Orlandini B,Pontecorvi V,Familiari P,Tringali A,Perri V,Costamagna G

    更新日期:2020-06-24 00:00:00

  • Hereditary pancreatitis for the endoscopist.

    abstract::Hereditary pancreatitis shares a majority of clinical and morphologic features with chronic alcoholic pancreatitis, but may present at an earlier age. The term hereditary pancreatitis has primarily been associated with mutations in the serine protease 1 gene (PRSS1) which encodes for cationic trypsinogen. PRSS1 mutati...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X12467565

    authors: Patel MR,Eppolito AL,Willingham FF

    更新日期:2013-03-01 00:00:00

  • EUS-guided FNA for biliary disease as first-line modality to obtain histological evidence.

    abstract:BACKGROUND:Few reports have described endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) for biliary lesions. In addition, adverse events were not completely examined in previous reports, due to the inclusion of cases in which biliary stents had already been placed. The present study aimed to investigate t...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X15625584

    authors: Onda S,Ogura T,Kurisu Y,Masuda D,Sano T,Takagi W,Fukunishi S,Higuchi K

    更新日期:2016-05-01 00:00:00

  • Screening colonoscopy bowel preparation: experience in an urban minority population.

    abstract:METHODS:Suboptimal bowel preparation, present in over 20% of colonoscopies, can severely compromise the effectiveness of the colonoscopy procedure. We surveyed 93 primarily urban minority men and women who underwent asymptomatic 'screening' colonoscopy regarding their precolonoscopy bowel-preparation experience. RESUL...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X13498661

    authors: Basch CH,Basch CE,Wolf RL,Zybert P,Lebwohl B,Shmukler C,Neugut AI,Shea S

    更新日期:2013-11-01 00:00:00

  • Secondary causes of nonalcoholic fatty liver disease.

    abstract::Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease rangi...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11430859

    authors: Kneeman JM,Misdraji J,Corey KE

    更新日期:2012-05-01 00:00:00

  • Correlation between serum gastrin and cellular proliferation in Barrett's esophagus.

    abstract:BACKGROUND:Patients with Barrett's esophagus (BE) are commonly treated with proton-pump inhibitors (PPIs) to minimize the exposure of esophageal mucosa to stomach acid. However, the use of these medications can lead to significant hypergastrinemia in a subset of patients, which is concerning due to the known tumorigeni...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X10392444

    authors: Green DA,Mlynarczyk CM,Vaccaro BJ,Capiak KM,Quante M,Lightdale CJ,Abrams JA

    更新日期:2011-03-01 00:00:00

  • External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection.

    abstract:Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284820977385

    authors: van Rossen TM,van Dijk LJ,Heymans MW,Dekkers OM,Vandenbroucke-Grauls CMJE,van Beurden YH

    更新日期:2021-01-09 00:00:00

  • The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

    abstract::Gut microbiota is a compilation of microorganisms dwelling in the entire mammalian gastrointestinal tract. They display a symbiotic relationship with the host contributing to its intestinal health and disease. Even a slight fluctuation in this equipoise may be deleterious to the host, leading to many pathological cond...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X12454590

    authors: Bien J,Palagani V,Bozko P

    更新日期:2013-01-01 00:00:00

  • Optimal use of biologics in the management of Crohn's disease.

    abstract::Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new opt...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X09357579

    authors: Panaccione R,Ghosh S

    更新日期:2010-05-01 00:00:00

  • Clinical outcome of patients with obscure gastrointestinal bleeding during antithrombotic drug therapy.

    abstract:Background:The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods:Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were en...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X17746930

    authors: Kono Y,Kawano S,Okamoto Y,Obayashi Y,Baba Y,Sakae H,Abe M,Gotoda T,Inokuchi T,Kanzaki H,Iwamuro M,Kawahara Y,Okada H

    更新日期:2018-01-14 00:00:00

  • Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

    abstract::The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X09346669

    authors: Olsen SK,Brown RS,Siegel AB

    更新日期:2010-01-01 00:00:00

  • The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study.

    abstract:Background:Nonalcoholic fatty liver disease (NAFLD) is correlated with low-grade inflammation and dietary habits. Until today, there have been limited epidemiologic data assessing the role of diet's inflammatory potential on NAFLD. The aim was to evaluate the relationship between an anti-inflammatory diet, as reflected...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819858039

    authors: Tyrovolas S,Panagiotakos DB,Georgousopoulou EN,Chrysohoou C,Skoumas J,Pan W,Tousoulis D,Pitsavos C

    更新日期:2019-06-23 00:00:00

  • Erratum for PMID 21180585.

    abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 已发布勘误

    doi:10.1177/1756283X10363751

    authors:

    更新日期:2012-09-01 00:00:00

  • Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection.

    abstract:Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819843002

    authors: Dehlholm-Lambertsen E,Hall BK,Jørgensen SMD,Jørgensen CW,Jensen ME,Larsen S,Jensen JS,Ehlers L,Dahlerup JF,Hvas CL

    更新日期:2019-04-10 00:00:00

  • Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.

    abstract::Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple cli...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756283X16638833

    authors: Kopylov U,Seidman E

    更新日期:2016-07-01 00:00:00

  • Evaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice.

    abstract::The wireless motility capsule (WMC) is an ambulatory noninvasive and nonradioactive diagnostic sensor that continuously samples intraluminal pH, temperature, and pressure as it moves through the gastrointestinal (GI) tract. This review summarizes the data obtained in clinical trials with the WMC and discusses its role...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X12437874

    authors: Tran K,Brun R,Kuo B

    更新日期:2012-07-01 00:00:00

  • Certolizumab pegol for the treatment of Crohn's disease.

    abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11413315

    authors: Schreiber S

    更新日期:2011-11-01 00:00:00

  • Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

    abstract::Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X10369922

    authors: Sanger GJ,Chang L,Bountra C,Houghton LA

    更新日期:2010-09-01 00:00:00

  • Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation.

    abstract::In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11410770

    authors: Pastorelli L,De Salvo C,Cominelli MA,Vecchi M,Pizarro TT

    更新日期:2011-09-01 00:00:00

  • Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

    abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X08094880

    authors: Lee YC,Liou JM,Wu MS,Wu CY,Lin JT

    更新日期:2008-09-01 00:00:00

  • Effectiveness of endoscopic ultrasound-guided drainage for noncapsulated postoperative pancreatic collection.

    abstract:Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756284819884418

    authors: Tamura T,Kitano M,Kawai M,Tanioka K,Itonaga M,Kawaji Y,Nuta J,Hatamaru K,Yamashita Y,Kitahata Y,Miyazawa M,Hirono S,Okada KI,Yamaue H

    更新日期:2019-10-24 00:00:00

  • Sex-based differences in inflammatory bowel diseases: a review.

    abstract::Sex-based differences in inflammatory bowel disease (IBD) pathogenesis, disease course, and response to therapy have been increasingly recognized, however, not fully understood. Experimental and translational models have been leveraged to investigate hypothesized mechanisms for these observed differences, including th...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章,评审

    doi:10.1177/1756284820915043

    authors: Rustgi SD,Kayal M,Shah SC

    更新日期:2020-04-28 00:00:00

  • Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

    abstract::Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...

    journal_title:Therapeutic advances in gastroenterology

    pub_type: 杂志文章

    doi:10.1177/1756283X11428502

    authors: Kelesidis T,Pothoulakis C

    更新日期:2012-03-01 00:00:00

  • Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma.

    abstract:Introduction:Hepatocholangiocarcinoma (HCC-ICC) is a rare tumor presenting the histologic characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). As there is no consensus on it management, the therapeutic strategy rests on the specific treatments for HCC or ICC. Programmed cell...

    journal_title:Therapeutic advances in gastroenterology

    pub_type:

    doi:10.1177/1756284820935189

    authors: Saint A,Benchetrit M,Novellas S,Ouzan D,Falk AT,Leysalle A,Barriere J

    更新日期:2020-06-20 00:00:00